<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://arxiv.org/abs/2201.09647">Original</a>
    <h1>AlphaFold-Powered Drug Discovery of a Novel CDK20 Inhibitor</h1>
    
    <div id="readability-page-1" class="page"><div id="content-inner">
  <div id="abs">
    
    
    <div><p><span>Authors:</span><a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Ren%2C+F">Feng Ren</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Ding%2C+X">Xiao Ding</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Zheng%2C+M">Min Zheng</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Korzinkin%2C+M">Mikhail Korzinkin</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Cai%2C+X">Xin Cai</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Zhu%2C+W">Wei Zhu</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Mantsyzov%2C+A">Alexey Mantsyzov</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Aliper%2C+A">Alex Aliper</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Aladinskiy%2C+V">Vladimir Aladinskiy</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Cao%2C+Z">Zhongying Cao</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Kong%2C+S">Shanshan Kong</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Long%2C+X">Xi Long</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Liu%2C+B+H+M">Bonnie Hei Man Liu</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Liu%2C+Y">Yingtao Liu</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Naumov%2C+V">Vladimir Naumov</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Shneyderman%2C+A">Anastasia Shneyderman</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Ozerov%2C+I+V">Ivan V. Ozerov</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Wang%2C+J">Ju Wang</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Pun%2C+F+W">Frank W. Pun</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Aspuru-Guzik%2C+A">Alan Aspuru-Guzik</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Levitt%2C+M">Michael Levitt</a>, <a href="https://arxiv.org/search/q-bio?searchtype=author&amp;query=Zhavoronkov%2C+A">Alex Zhavoronkov</a></p></div>
      
    
  
    <p><a href="https://arxiv.org/pdf/2201.09647">Download PDF</a></p><blockquote>
      <span>Abstract:</span>  The AlphaFold computer program predicted protein structures for the whole
human genome, which has been considered as a remarkable breakthrough both in
artificial intelligence (AI) application and structural biology. Despite the
varying confidence level, these predicted structures still could significantly
contribute to the structure-based drug design of novel targets, especially the
ones with no or limited structural information. In this work, we successfully
applied AlphaFold in our end-to-end AI-powered drug discovery engines
constituted of a biocomputational platform PandaOmics and a generative
chemistry platform Chemistry42, to identify a first-in-class hit molecule of a
novel target without an experimental structure starting from target selection
towards hit identification in a cost- and time-efficient manner. PandaOmics
provided the targets of interest and Chemistry42 generated the molecules based
on the AlphaFold predicted structure, and the selected molecules were
synthesized and tested in biological assays. Through this approach, we
identified a small molecule hit compound for CDK20 with a Kd value of 8.9 +/-
1.6 uM (n = 4) within 30 days from target selection and after only synthesizing
7 compounds. To the best of our knowledge, this is the first reported small
molecule targeting CDK20 and more importantly, this work is the first
demonstration of AlphaFold application in the hit identification process in
early drug discovery.

    </blockquote>

    <!--CONTEXT-->
    
  </div>
</div><div>
      <h2>Submission history</h2><p> From: Alex Zhavoronkov [<a href="https://arxiv.org/show-email/9e2c6f96/2201.09647">view email</a>]
      </p></div></div>
  </body>
</html>
